| Drug General Information |
| Drug ID |
D0US9O
|
| Former ID |
DIB019301
|
| Drug Name |
compound 19a
|
| Drug Type |
Small molecular drug
|
| Indication |
Discovery agent
|
Investigative |
[1]
|
|---|
| Structure |
|
Download
2D MOL
|
| Formula |
C16H16FN9
|
| InChI |
InChI=1S/C16H16FN9/c1-9(13-19-5-10(17)6-20-13)22-16-24-14-11(3-4-18-14)15(25-16)23-12-7-26(2)8-21-12/h3-9H,1-2H3,(H3,18,22,23,24,25)/t9-/m0/s1
|
| InChIKey |
QHXBWJSQXSYAGG-VIFPVBQESA-N
|
| PubChem Compound ID |
|
| PubChem Substance ID |
|
| Target and Pathway |
| Target(s) |
Tyrosine-protein kinase JAK2 |
Target Info |
Inhibitor |
[1]
|
|---|
| JAK1 |
Target Info |
Inhibitor |
[1]
|
| Tyrosine-protein kinase JAK3 |
Target Info |
Inhibitor |
[1]
|
|
KEGG Pathway
|
Chemokine signaling pathway
|
|
PI3K-Akt signaling pathway
|
|
Signaling pathways regulating pluripotency of stem cells
|
|
Jak-STAT signaling pathway
|
|
Cholinergic synapse
|
|
Prolactin signaling pathway
|
|
Adipocytokine signaling pathway
|
|
Leishmaniasis
|
|
Toxoplasmosis
|
|
Tuberculosis
|
|
Measles
|
|
Influenza A
|
|
Herpes simplex infectionhsa04151:PI3K-Akt signaling pathway
|
|
Osteoclast differentiation
|
|
Hepatitis C
|
|
Hepatitis B
|
|
HTLV-I infection
|
|
Herpes simplex infection
|
|
Epstein-Barr virus infection
|
|
Pathways in cancer
|
|
Viral carcinogenesis
|
|
Pancreatic cancerhsa04062:Chemokine signaling pathway
|
|
Primary immunodeficiency
|
|
NetPath Pathway
|
IL2 Signaling Pathway
|
|
PANTHER Pathway
|
Inflammation mediated by chemokine and cytokine signaling pathway
|
|
Interferon-gamma signaling pathway
|
|
JAK/STAT signaling pathway
|
|
PDGF signaling pathway
|
|
PI3 kinase pathway
|
|
CCKR signaling map STP00005:Angiogenesis
|
|
PDGF signaling pathwayP00036:Interleukin signaling pathway
|
|
Pathway Interaction Database
|
Endothelins
|
|
ErbB4 signaling events
|
|
GMCSF-mediated signaling events
|
|
IL4-mediated signaling events
|
|
IL27-mediated signaling events
|
|
Signaling events mediated by PTP1B
|
|
IL12-mediated signaling events
|
|
S1P3 pathway
|
|
SHP2 signaling
|
|
CXCR4-mediated signaling events
|
|
IL5-mediated signaling events
|
|
IFN-gamma pathway
|
|
ErbB2/ErbB3 signaling events
|
|
IL3-mediated signaling events
|
|
IL6-mediated signaling events
|
|
PDGFR-beta signaling pathway
|
|
IL23-mediated signaling events
|
|
Signaling events mediated by Stem cell factor receptor (c-Kit)
|
|
EPO signaling pathway
|
|
Notch-mediated HES/HEY networkp73pathway:p73 transcription factor network
|
|
Signaling events mediated by TCPTP
|
|
IL2-mediated signaling events
|
|
IL2 signaling events mediated by PI3K
|
|
PDGFR-alpha signaling pathway
|
|
IL2 signaling events mediated by STAT5il4_2pathway:IL4-mediated signaling events
|
|
CD40/CD40L signaling
|
|
IL2 signaling events mediated by STAT5
|
|
Reactome
|
Interleukin-6 signaling
|
|
MAPK3 (ERK1) activation
|
|
MAPK1 (ERK2) activation
|
|
GPVI-mediated activation cascade
|
|
Prolactin receptor signaling
|
|
RMTs methylate histone arginines
|
|
G beta:gamma signalling through PI3Kgamma
|
|
Interleukin-3, 5 and GM-CSF signaling
|
|
RAF activation
|
|
RAF/MAP kinase cascade
|
|
Interferon gamma signaling
|
|
Regulation of IFNG signaling
|
|
Interleukin receptor SHC signaling
|
|
Growth hormone receptor signaling
|
|
Factors involved in megakaryocyte development and platelet productionR-HSA-1059683:Interleukin-6 signaling
|
|
ISG15 antiviral mechanism
|
|
Interleukin-7 signaling
|
|
Interleukin-2 signaling
|
|
Interferon alpha/beta signaling
|
|
Regulation of IFNA signalingR-HSA-114604:GPVI-mediated activation cascade
|
|
WikiPathways
|
Serotonin Receptor 2 and STAT3 Signaling
|
|
Type II interferon signaling (IFNG)
|
|
Notch Signaling Pathway
|
|
EPO Receptor Signaling
|
|
EGF/EGFR Signaling Pathway
|
|
IL-4 Signaling Pathway
|
|
IL-6 signaling pathway
|
|
Kit receptor signaling pathway
|
|
IL-3 Signaling Pathway
|
|
Mesodermal Commitment Pathway
|
|
Interleukin-2 signaling
|
|
Signaling by SCF-KIT
|
|
Prolactin receptor signaling
|
|
Growth hormone receptor signaling
|
|
JAK/STAT
|
|
BDNF signaling pathway
|
|
Oncostatin M Signaling Pathway
|
|
Interleukin-11 Signaling Pathway
|
|
AGE/RAGE pathway
|
|
TSLP Signaling Pathway
|
|
IL17 signaling pathway
|
|
Leptin signaling pathway
|
|
TSH signaling pathway
|
|
Interleukin-3, 5 and GM-CSF signaling
|
|
Interferon gamma signaling
|
|
Factors involved in megakaryocyte development and platelet production
|
|
IL-5 Signaling PathwayWP619:Type II interferon signaling (IFNG)
|
|
Interferon type I signaling pathways
|
|
TGF Beta Signaling Pathway
|
|
IL-2 Signaling Pathway
|
|
TCA Cycle Nutrient Utilization and Invasiveness of Ovarian Cancer
|
|
Interleukin-7 signaling
|
|
PDGF Pathway
|
|
Prostate Cancer
|
|
IL-9 Signaling Pathway
|
|
Type III interferon signaling
|
|
IL-7 Signaling Pathway
|
|
Integrated Breast Cancer Pathway
|
|
Integrated Cancer pathway
|
|
Interferon alpha/beta signaling
|
|
IL-5 Signaling PathwayWP49:IL-2 Signaling Pathway
|
| References |
| REF 1 | Discovery of 1-methyl-1H-imidazole derivatives as potent Jak2 inhibitors. J Med Chem. 2014 Jan 9;57(1):144-58. |
|---|
